JOHNSON & JOHNSON SEC 10-Q Report

Johnson & Johnson, a global leader in the healthcare industry, has released its Form 10-Q report for the third quarter, showcasing robust financial and operational performance. The report highlights significant growth in sales, profitability, and strategic business initiatives, underscoring the company's strong market position and future outlook.

Financial Highlights

• Sales to customers: $23,743 million, representing a 5.8% increase compared to the same period last year.
• Gross profit: $16,115 million, reflecting a gross margin of 67.9% compared to 69.4% in the prior year period.
• Earnings before provision for taxes on income: $6,491 million, indicating a 12.9% increase from the previous year.
• Net earnings: $5,537 million, showing an 18.2% increase from the prior year period.
• Basic net earnings per share: $2.30, compared to $1.95 in the previous year, reflecting strong earnings growth.
• Diluted net earnings per share: $2.29, up from $1.93 in the prior year, indicating improved profitability.

Business Highlights

• Revenue Segments: The Innovative Medicine segment saw significant growth in oncology, with products like DARZALEX and ERLEADA showing strong performance. The MedTech segment also experienced growth, particularly in cardiovascular and electrophysiology products.
• Geographical Performance: The United States market showed a 7.8% increase in sales, driven by strong performance in both Innovative Medicine and MedTech segments. Europe and Asia-Pacific regions also contributed to growth, with Europe seeing a 3.3% increase and Asia-Pacific, Africa regions experiencing a 4.4% rise.
• New Product Launches: The acquisition of Intra-Cellular Therapies, Inc. introduced CAPLYTA, a treatment for bipolar I and II depression and schizophrenia, expanding the company's portfolio in mental health.
• Future Outlook: The company is preparing for bellwether trials in consolidated proceedings in California and New Jersey, indicating a focus on resolving ongoing legal matters related to talc claims. Additionally, the company is assessing the impact of new tax legislation, which may affect future financial performance.

SEC Filing: JOHNSON & JOHNSON [ JNJ ] - 10-Q - Jul. 24, 2025